UroGen Pharma Ltd.

Good day, and thank you for standing by. Welcome to the 2024 Second Quarter Urgent Pharma Earnings Call. At this time, all participants are in listen-only mode. After this speaker's presentation, there will be a question and answer session. To ask a question during this session, you'll need to press star 11 on your telephone. You will then hear an automated message advising your hand is raised. To withdraw your question, please press star 1-1 again. Please be advised that today's conference is being recorded. I would now like to hand the conference over to your first speaker today, Vincent Perron, Head of Investor Relations. Please go ahead.

Thank you, Operator.

Good morning, everyone, and welcome to Eurogen Pharma's second quarter 2024 financial results and business update conference call. Earlier this morning, we issued a press release providing an overview of our recent corporate highlights and financial results for the quarter ended June 30, 2024. The press release can be accessed on the investors portion of our website at investors.eurogen.com. Joining me today are Liz Barrett, President and Chief Executive Officer, Dr. Mark Schoenberg, Chief Medical Officer, David Lin, Chief Commercial Officer, and Don Kim, Chief Financial Officer. During today's call, we will be making certain forward-looking statements. These may include statements regarding our ongoing commercialization activities related to gel mito, our ongoing and planned clinical trials, commercial and clinical milestones, market and revenue opportunities, our commercialization strategy and expectation, as well as potential future commercialization activities for UGN 102 if approved. Anticipated data, regulatory filings, and decisions including UGN 102 potentially receiving priority review, EGN 102 being a primary road driver for Eurogen, if approved, future research and development efforts, our public goals, and 2024 financial guidance, among other things. These forward-looking statements are based on current information, assumptions, and expectations that are subject to change. A description of potential risks can be found in our earnings press release and latest SEC disclosure documents. You are cautioned not to place undue reliance on these forward-looking statements, and your agenda explains any obligation to update these statements. I'll now turn the call over to Liz Barrett, President and CEO.